Tony Anderson @anderswimmer

Enjoy every moment

Born on this day in 1923: Bob Chappuis 🇺🇸〽️ WWII gunner whose plane was shot down over Italy. Hidden for 3 months. Returned to lead Michigan’s 1947 national champions. Rose Bowl MVP. Heisman runner-up. Clip: 61-yard TD to Bob Mann in a 49-13 win over Stanford. #GoBlue

Mike Tirico is getting his due after a dominant stretch across NBC’s biggest stages. After calling the Super Bowl and hosting Olympic primetime coverage, Tirico has separated himself as the network’s—and arguably the industry’s—best all-around sportscaster.

Scott Van Pelt pays tribute to Mike Tirico on SportsCenter in his One Big Thing. "What he did on Sunday I believe moves him to a place occupied by one person in our business - him."

41 years ago today, Bobby Knight threw a chair.

I wouldn't argue with this list of two.

Rob Oviatt @RobOviatt1

4 months ago

The two best Olympic hosts in my lifetime. They set the standard. @Johnubacon @TimBrando @Olympics

keyboard_arrow_left Previous keyboard_arrow_right Next

1 0 18 14K 0

Tim Anderson sacks “The U” in Michigan’s 1984 season opener #SundaySacks Michigan defeated Jimmy Johnson's defending national champion and No. 1 ranked Miami Hurricanes by a score of 22-14, breaking Miami's 13-game winning streak. One Team. One Legacy. #GoBlue

When BCG is given, the tumor finds a way to hide from T cells. So taking off the brakes from T cells using checkpoint inhibitors alone won't work. This study confirms this. NK cells matter and that is how ANKTIVA is different.

@Dub__A Charlie Rich?

Working to explain to the world how and why Bioshield works. T cells and NK cells kill cancer, that’s irrefutable. Low NK cells and T cells means cancer grows, that’s irrefutable. So if there is a drug available to boost NK and T cells then there is better chance to kill the cancer cell of any tumor type – That’s the how and it is that simple. 1. NK and T cells (lymphocytes) kill cancer… causation 2. Anktiva proliferates, grows and activates NK and T cells in the body... causation (and in the FDA approved label) 3. Adding Anktiva to current standards of care have shown prolonged survival in patients with cancer across multiple tumor types since it is treating the immune system... causation. That is the HOW! Anktiva the Bioshield is the first immunotherapy in history of medicine that is FDA approved with a mechanism of action to grow and supercharge NK and T cells in the body, generate memory T cells and restore the immune system without stimulating immunosuppressive T cells. Now what's next? We can measure low NK and T cells (lymphopenia) with a simple blood test (ALC). This is no different than the same test measuring low red blood cells (anemia) or low neutrophils (neutropenia). Low NK and T cells are called lymphopenia. Ask your doctor what is my ALC? (absolute lymphocyte count) Today, FDA has approved EPOGEN to treat anemia regardless of cancer type and has approved NEUPOGEN to treat neutropenia regardless of cancer type. So, based on the mechanism of action of ANKTIVA and the irrefutable causation that NK cells and T cells kill cancer, ANKTIVA should be enabled to treat patients with low NK and T cells (lymphopenia) regardless of tumor type. Especially since ANKTIVA, by activating NK and T cells (reversing lymphopenia) is the only FDA APPROVED mechanism of action in the label to generate MEMORY T CELLS. This supercharging of the immune system happens regardless of the cancer type and we have now shown in completed clinical trials across multiple tumor types including lung cancer (NSCLC), small-cell lung cancer (SCLC), urothelial carcinoma, head and neck cancer, melanoma, colorectal cancer, cervical cancer, renal cell carcinoma, gastric cancer, and hepatocellular carcinoma (manuscript in progress) that by increasing NK and T cells, we induce prolonged survival in patients who have failed all standards of care including current immunotherapy with checkpoint inhibitors. This mechanism of action has already been approved showing long term complete responses, but approved only for an orphan state of a subset of bladder cancer. So, if ANKTIVA could receive the same consideration as EPOGEN and NEUPOGEN as an immune supportive agent, many patients could benefit now without having to fly to LA. I hope we can change that quickly and change the lives of countless of desperate patients in which all standards of care have failed. Working hard to change the course of cancer everyday. The paradigm change is we are treating the immune system, regardless of its cancer type. Cancer is the symptom and the collapse of the immune system is the root cause.

#Bioshield #ANKTIVA REPOST! LET'S GO VIRAL

Rob Oviatt @RobOviatt1

4 months ago

The two best Olympic hosts in my lifetime. They set the standard. @Johnubacon @TimBrando @Olympics

keyboard_arrow_left Previous keyboard_arrow_right Next

1 0 18 14K 0

DR Patrick Soon has found a way to CURE CANCER - Make this go VIRAL. Nothing is better as the God-given immune system - Thankfully this doctor has figured out how to activate the immune system to heal Cancer. Make this go Viral to help people with cancer.

Camus @newstart_2024

8 months ago

A Cancer Breakthrough That Changes Everything In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments

134 2K 7K 422K 6K

A Medical Paradigm Built on Warfare is Failing Cancer Patients. Here’s the Breakthrough They Are Blocking. Dr. Patrick Soon-Shiong reveals a hard truth: our cancer treatment roots are in mustard gas & nuclear weapons—a system of "short-term survival scarred by fear, power, and control." He believed groundbreaking science would be embraced. He was wrong. The discovery? Your body has the ultimate weapon: the Natural Killer (NK) cell. We can now activate it with a simple protein (IL-15), creating a universal key to attack ALL cancer types. The FDA’s fatal flaw? Bureaucratic inertia & regulatory capture. They approve drugs for anemia (Epogen) or low neutrophils (Neupogen) regardless of tumor type. It's logical: you don't ask why you need a blood transfusion. Yet, when patients have low NK & T cells (lymphopenia)—a $20 test reveals this—the FDA refuses to approve IL-15 as the universal solution. It's like denying a transfusion for catastrophic blood loss. The proof is there: - ✅ Bladder cancer patients alive & cancer-free for 10+ years. - ✅ Data for pancreatic, lung, & head/neck cancers. The response? "Refused to file." They demand a randomized trial for every single cancer type—a process requiring "three lifetimes" while patients die. This isn't just about cancer. The immune system is the key to longevity. The world's oldest person, 117, had hyper-active NK cells. We have a simple, subcutaneous shot that can save lives now. The system, prioritizing money & consensus over people, is standing in the way. It's time for a revolution in medicine. The power to heal is already within us.

The power within all of us to fight cancer. The disease is the collapse of the immune system regardless of the type of tumor.

The Megyn Kelly Show @MegynKellyShow

9 months ago

“This should be available for the rest of the country…” @drpatrick on why he believes Trump can implement his plan to prevent and cure cancer. Watch and download: podcasts.apple.com/us/podcast/the…

73 680 3K 130K 862

“This should be available for the rest of the country…” @drpatrick on why he believes Trump can implement his plan to prevent and cure cancer. Watch and download: podcasts.apple.com/us/podcast/the…

3️⃣5️⃣ today 👍

@Dub__A Happy Birthday Andrew!

$IBRX there is only one remedy to clear COVID and mRNA vaccine from our body, that is #bioshield #ANKTIVA by @drpatrick BARDA need to fund @ImmunityBio NOW!

NCI supported PRAGMATICA lung trial failed but established real world survival after chemo of 9 mo. Our Bioshield trial in lung patients who progressed show when NK & T cells are activated, survival is doubled & some patients live 4+ yrs in late stage of cancer Coming this week

PEM needs to be studied and regarded as an injury. It's just not a pesky nuisance / symptom exacerbation.